ADMINISTRATION OF SUMO-ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS Russian patent published in 2024 - IPC A61K31/505 A61K45/06 C07D471/04 A61P35/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to use [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methylsulphamate or a pharmaceutically acceptable salt thereof for treating a patient suffering from cancer, in combination with a checkpoint inhibitor selected from an anti-PD-1 antibody and anti-CTLA-4 antibodies, wherein the cancer is selected from colorectal cancer, lymphoma, leukaemia and lung cancer.

EFFECT: present invention provides a synergistic effect of the combination [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl) pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methylsulphamate (compounds I-263a) with a checkpoint inhibitor.

32 cl, 34 dwg, 2 ex